Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SKELID is an oral small-molecule tablet approved in 1997 by Sanofi for an undisclosed indication. The mechanism of action and specific therapeutic area remain unspecified in available data.
With LOE approaching, commercial teams should expect resource reallocation and reduced headcount; this is a mature product in managed decline.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SKELID presents minimal career opportunity with zero linked job openings and approaching loss of exclusivity. Working on this product offers defensive career experience in managed decline and generic transition rather than growth opportunities.
Worked on SKELID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.